Hone Health Leverages Biomarker Testing for Personalized US Heart Health Supplement Program
Hone Health's new cardiovascular supplement program uses blood biomarker testing to tailor nutrition recommendations, shifting the market from broad cholesterol-focused approaches to individualized healthspan and metabolic insights.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
New York-based telehealth firm Hone Health has launched a personalised cardiovascular supplement program in the United States, integrating blood biomarker testing to guide bespoke nutrition recommendations. This initiative signals a strategic pivot in the heart health supplement sector, moving beyond traditional, broad-spectrum approaches to a more nuanced, individualised model. The firm's consulting physician and scientific advisor, Dr. Abid Husain, noted that consumers increasingly view heart health through a wider lens, encompassing inflammation, metabolic function, and overall healthspan, rather than solely focusing on cholesterol metrics.
Hone Health's approach underscores a growing industry trend towards advanced biomarker utilisation. Dr. Husain indicated that traditional heart health strategies often overemphasise cholesterol. However, advanced biomarkers offer a comprehensive view of cardiovascular risk, including inflammation and metabolic health. This expanded perspective necessitates a corresponding evolution in supplement recommendations, positioning them as one component within a broader strategy that combines biomarker testing, professional guidance, lifestyle adjustments, and, when appropriate, medication. Recommendations are thus formulated based on individual lab results, medical history, and specific risk factors, moving away from a 'one-size-fits-all' paradigm.
The launch capitalises on significant market expansion. Grand View Research estimated the US cardiovascular health supplements market reached $2.11 billion in 2024, projecting a compound annual growth rate (CAGR) of 7.61% through 2030. Hone Health aims to identify cardiovascular risk earlier by examining factors beyond standard cholesterol measures, asserting that proactive intervention during the 'window' where lifestyle and metabolic adjustments are most effective can significantly alter disease trajectory.
This shift aligns with increasing scientific interest in personalised nutrition. A May 2024 Nature Medicine trial, while focused on dietary interventions, demonstrated the efficacy of personalised advice in reducing central adiposity and triglyceride concentrations. Dr. Husain highlighted that nutraceutical ingredients often affect multiple biological pathways concurrently, making personalization increasingly vital as more biomarker data becomes available. He anticipates that biomarker-guided nutrition will redefine how cardiovascular supplements are developed and marketed, necessitating greater transparency and scientific backing from brands.
What this means for United States
US manufacturers must invest in R&D to develop ingredient combinations optimised for specific biomarker profiles, moving beyond single-ingredient formulations. Brand owners face a significant opportunity to capture market share by offering personalised product lines, requiring increased marketing spend on consumer education regarding biomarker benefits. Regulatory teams should anticipate increased scrutiny from the FDA regarding biomarker-based claims and ensure robust scientific substantiation is in place for all product labelling and promotional materials, impacting claim substantiation costs by an estimated 10-15%. Companies failing to adapt to this personalisation trend risk market erosion from agile competitors and D2C brands offering tailored solutions, potentially compressing margins on generic SKUs by Q4 2027.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.